SCHEMBL789716

SCHEMBL789716

COc1ncc(Br)cc1NS(=O)(=O)CC(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.42
S100A9 P06702 3/20 0.39
LRRK2 Q5S007 1/20 0.38
PIK3CA P42336 7/20 0.36
PIK3CD O00329 6/20 0.36
PIK3CG P48736 4/20 0.36
PIK3CB P42338 3/20 0.36
BRAF P15056 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC22A12 Q96S37 1/20 0.34
MTOR P42345 1/20 0.34
SHMT2 P34897 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17969358 0.85 HPGD (0.44) S100A9PIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL15653017 0.83 CYP17A1 (0.41) CYP17A1S100A9LRRK2PIK3CAPIK3CD
SCHEMBL791104 0.83 MAPT (0.48) CYP17A1S100A9LRRK2PIK3CAPIK3CD
SCHEMBL790767 0.82 PTGS1 (0.45) S100A9MEN1POLBKMT2ASLC22A12
SCHEMBL16551863 0.81 PIK3CA (0.47) CYP17A1PIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL29556703 0.79 PIK3CD (0.52) PIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL114826 0.79 PIK3CD (0.52) PIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL3117652 0.78 PIK3CG (0.44) S100A9PIK3CAPIK3CDPIK3CGPIK3CB
Ammonia Solution, Strong SCHEMBL28553362 0.77 PIK3CD (0.51) PIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL789611 0.77 ALDH1A1 (0.52) CYP17A1PIK3CGBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2958564-B1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS CALITOR SCIENCES LLC (US) 2018-05-09 EP disclosed
US-9573953-B2 Heteroaromatic compounds as PI3 kinase modulators and methods of use CALITOR SCIENCES, LLC (US) 2017-02-21 US disclosed
EP-2958564-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS Calitor Sciences, LLC (US) 2015-12-30 EP disclosed
WO-2014130375-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS CALITOR SCIENCES, LLC (US) 2014-08-28 WO disclosed
US-20140234254-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-21 US disclosed
WO-2012037108-A1 AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
WO-2012037108-A1 AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140234254-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE PIK3R1, PIK3R3, AKT3 CYP17A1 1380/4885S100A9 4675/4885LRRK2 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.